Dr. Gary Grohmann, Director of the Australian Immunisation Coalition talks about the possible role AVM0703 may play in treating some of the systems associated with COVID-19.

AVM0703 is a repurposed small molecule that is under investigation for treating lymphoid malignancies. In addition to the possibility of being a novel cancer treatment option, the drug is also under investigation to treat patients with COVID-19 since it works by activating a persons immune system.

AVM0703 is just one of several approaches that are in develop to treat patients with COVID-19. In the second video clip below, Dr. Grohmann lists the pros and cons of vaccines, anti-viral agents and immune response agents to treat COVID-19.

For more information, visit the AVM Biotechnology website: http://avmbiotech.com/.